Site Search

DEUTSCH All Languages

Companies in the News

Ablynx (EBR:ABLX) ABLYNX PROVIDES A BUSINESS UPDATE FOR THE THIRD QUARTER 2008

Ablynx (EBR:ABLX) REGULATED INFORMATION

GHENT, Belgium, 19 November 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, today provides its non-audited business update, in compliance with the EU transparency directive, summarising material events and Ablynx's financial position for the third quarter of 2008 and approved by the Board of Directors on 19 November 2008.

Q3 2008 Highlights

* On track to announce, by year end, data from multi-dose Phase Ib study in patients for its novel anti-thrombotic ALX-0081 * Filed an IND equivalent for ALX-0681, a subcutaneous delivery form of ALX-0081 * On track to reach the target of initiating 6-8 new Nanobody® programmes in 2008 * 38% increase in revenue to €9.4 million for the nine month period (2007: €6.8 million) * Entered into a co-discovery and co-development collaboration with Merck Serono to co-develop Nanobodies® against two targets with the opportunity to co-share in the profits of products which reach market and received a €10 million upfront fee * Boehringer Ingelheim extended the research funding of its Alzheimer's disease collaboration with Ablynx for another year * Increased staff by 14 people during the quarter, to reach a total of 187 at 30 September * Secured the rights to 7,000m² of cutting-edge laboratory facilities which will be to be completed by mid-2010 * €119.8 million in cash at 30 September 2008

Ablynx provided an R&D update on October 10th during which a new preclinical development programme, ALX-0141, a Nanobody® against RANKL, an important target for bone disorders such as osteoporosis, was presented. Ablynx also announced at the R&D Day the successful generation of Nanobodies® against several GPCRs with picomolar activity in functional cellular assays such as chemotaxis and cell mobility. In October a €1.8 million grant was approved by the Flemish government to explore "Novel methods for uses of Nanobodies®". In November Ablynx presented interim data from the Phase 1b study in patients with stable angina at the American Heart Association Conference in New Orleans.

For more information, please contact: College Hill Life Sciences - for UK/International media enquiries: Sue Charles, Justine Lamond, John McIntyre t: +44 (0)20 7866 7857 f: +44 (0)20 7866 7900 e: ablynx@collegehill.com

Ablynx: Dr Edwin Moses Chairman and CEO t: +32 (0)9 262 00 07 m: +44 (0)7771 954 193 / +32 (0)473 39 50 68 e: edwin.moses@ablynx.com

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

LINK: http://hugin.info/137912/R/1271534/281991.pdf

Ablynx

http://www.ablynx.com

ISIN: BE0003877942

Stock Identifier: XBRU.ABLX

Verbundene Unternehmen

Ablynx

ABN Newswire Diese Seite wurde besucht: (letzten 7 Tagen: 6) (letzten 30 Tagen: 18) (seit Veröffentlichung: 1100)